To the Editor,

Chimeric antigen receptor T (CAR-T) cells are not satisfying in treating solid tumors \[[@CR1]\]. PD-1 limits CAR-T cell therapy within solid tumors. CRISPR/cas9 can downregulate PD-1 \[[@CR2]\] but also potentially leads to carcinogenesis, because success of such tools relies on suppressing DNA damage response \[[@CR3]\]. Furthermore, CRISPR/cas9 could bring in missense mutations that might exacerbate T cell dysfunction. Hence, we need safer and more precise gene-editing tools to produce better CAR-T cells. *N*-linked glycosylation can stabilize PD-1 to compromise anti-tumor immunity \[[@CR4]\]. As *N*-linked glycosylation is restricted on asparagine coded by aac or aat, adenine base editors (ABE) can convert a·t to g·c base pair \[[@CR5]\], and may be used to diminish such glycosylation. Herein, we explored the potentials of ABE to edit and downregulate PD-1 in CAR-T cells.

Mutated PD-1 at N74 had decreased surface expression (Fig. [1](#Fig1){ref-type="fig"}a). Therefore, N74 in PD-1 is a good target for ABE. Three types of amino acids may be produced after base editing at N74 coded by aac (Fig. [1](#Fig1){ref-type="fig"}b). All 3 types of mutations into D74 (gac), S74 (agc), and G74 (ggc) comparably downregulated the surface and total PD-1 (*P* \< 0.001) (Fig. [1](#Fig1){ref-type="fig"}c and Additional file [1](#MOESM1){ref-type="media"}: Figure S1c). Next, we investigated whether ABE was able to decrease PD-1 in CAR-T cells. The delivery of gRNA using lentivirus is efficient \[[@CR6]\], so we constructed lentiviral vectors simultaneously expressing mesothelin-directed CAR and gRNA targeting non-specific sites (scramble) or N74 of *PDCD1* (gRNA), under 2 independent promoters (Additional file [1](#MOESM1){ref-type="media"}: Figure S1a). T cell transduction efficacies were over 85% (Additional file 1: Figure S1b). Then the commercially synthesized ABE proteins were delivered into CAR-T cells by electroporation. Sequencing data showed the conversion to g majorly happened from the first adenine within N74 codon of *PDCD1* in CAR-T cells expressing specific gRNA (Fig. [1](#Fig1){ref-type="fig"}d). Conversion was also noticed at the second adenine with lower frequencies (Fig. [1](#Fig1){ref-type="fig"}d). This editing pattern is consistent with previous report \[[@CR7]\]. Fig. 1Mutations of N74 decreased PD-1. **a** Surface expressions of wild-type PD-1 and its derivate N74A (A74) mutation in 293 T cells. **b** Potential mutations resulted from single-nucleotide conversions at N74. **c** Mutations at N74 decreased surface expression of PD-1. PD-1 harboring wild-type or mutated N74 were tandemly linked with self-cleaving P2A and GFP, then transiently expressed in 293 T cells. Surface PD-1 expression was determined in GFP^+^ cells by FACS assay. **d** Sanger sequencing of *PDCD1* of CAR-T cells expressing scramble or N74-targeted gRNA after base editing. **e--j** CAR-T cells having comparable rates of GFP^+^ cells were activated with equal amounts of anti-CD3/CD28 beads without exogenous cytokines. **e** Western blots of PD-1 in CAR-T cells activated or not. **f** qRT-PCR detecting PD-1 expressions in resting and activated CAR-T cells. **g** Surface expressions of PD-1 in CAR-T cells before and after activation. And mean fluorescence intensity (MFI) values were compared. **h** CAR-T cells were stained with eFluor 670 dyes and then continued to culture with or without beads. Forty-eight hours later, proliferations of CAR-T cells were determined according to eFlour 670 dilution. Activation markers, CD69 (**i**) and CD27 (**j**) were detected and compared in different CAR-T cells before and after activation. \*\**P* \< 0.01 and \*\*\*\**P* \< 0.001

In following experiments, the ratios of CAR-expressing cells were comparably adjusted to 85%. In gRNA CAR-T cells, PD-1 expression was decreased at protein level but not at mRNA level (Fig. [1](#Fig1){ref-type="fig"}e and f). Consistently, surface PD-1 was remarkably decreased in resting and activated gRNA CAR-T cells (*P* \< 0.01) (Fig. [1](#Fig1){ref-type="fig"}g). Further analysis suggested that ABE editing did not impair the proliferation and activation of CAR-T cells (*P* \> 0.05) (Fig. [1](#Fig1){ref-type="fig"}h--j) when PD-L1 was absent. Then mesothelin-positive cells with high PD-L1 expression were prepared (Fig. [2](#Fig2){ref-type="fig"}a). After washing out exogenous cytokines, CAR-T cells and target cells were co-incubated. Upon target cell engagement, CAR-T cells divided efficiently (Fig. [2](#Fig2){ref-type="fig"}b). Compared with gRNA counterparts, the proliferations of CAR-T cells expressing scramble RNA were significantly suppressed (*P* \< 0.05) (Fig. [2](#Fig2){ref-type="fig"}b). gRNA CAR-T cells had enhanced cytolytic capacities (*P* \< 0.05) and increased secretions of IL-2 and IFN-γ (*P* \< 0.05) after activation by tumor cells (Fig. [2](#Fig2){ref-type="fig"}c and d). To further confirm the effectiveness of ABE in relieving T cell inhibition, we checked the anti-tumor functions of CAR-T cells in vivo. Consistently, CAR-T cells expressing N74-targeted gRNA attained greater expansion (*P* \< 0.05) (Fig. [2](#Fig2){ref-type="fig"}e and Additional file [2](#MOESM2){ref-type="media"}: Figure S2). Decreased surface PD-1 (*P* \< 0.01) and upregulated activation markers (CD69 and CD27) (*P* \< 0.05) were noticed on gRNA CAR-T cells (Fig. [2](#Fig2){ref-type="fig"}f and g). gRNA CAR-T cells more efficiently delayed tumor growth and improved overall survival when compared with scramble counterparts (*P* \< 0.05) (Fig. [2](#Fig2){ref-type="fig"}h--j) (Additional files [3](#MOESM3){ref-type="media"} and [4](#MOESM4){ref-type="media"}). Fig. 2Single base conversion reduced PD-1-mediated suppression. **a** IFN-γ (100 IU/mL) induced PD-L1 expression in target cells. After that, target cells were washed to discard IFN-γ and used in following experiments. **b--d** CAR-T cells were co-incubated with target cells without exogenous cytokines. **b** CAR-T cells expanded with or without target cells for 48 h. **c** CAR-T cells were co-cultured with target cells at indicated effector to target ratios (E:T) for 24 h. The cytolytic potencies of CAR-T cells were tested using bioluminescence imaging. **d** CAR-T cells were incubated with tumor cells at E:T = 1:1. Twenty-four hour later, IL-2 and IFN-γ in supernatants were detected using ELISA. **e**--**j** The anti-tumor effects of ABE-edited CAR-T cells in vivo. **e** Five days after infusion, the ratios of infiltrated T cells (CD45^+^CD3^+^) were determined using flow cytometry after excluding dead cells (*n* = 4 per group). **f**, **g** The expressions of PD-1, CD69, and CD27 were detected in infiltrated T cells. In addition, effects of CAR-T cells on tumor growth (**h, i**) and survival of mice (**j**) were monitored weekly (each group had 5 mice). \**P* \< 0.05 and \*\**P* \< 0.01

Single base editing can modulate the stability and function of target protein by changing a single residue \[[@CR8]\]. Our work further uncovered the potential of such editing tool in T cells. Compared with CRISPR/cas9, ABE has narrower editing window and much less frequent off-target events \[[@CR9]\], representing a safer and more precise approach for gene editing. ABE-mediated point mutation can downregulate the inhibitory PD-1, therefore providing an alternative approach to augment T cell immunotherapy.
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**Additional file 1: Figure S1.** CAR-T cell construction**.** (**a**) Structure of lentiviral vector simultaneously delivering CAR and gRNA. (**b**) Transduction efficacy of T cells. Transduction efficacies were determined by GFP expression on day 5, before performing single base editing on the same day. (**c**) Vectors coding wild type (N74) or mutated (D74, S74 or G74) PD-1 were transiently transfected into 293 T cells. 48 hours later, cell lysis was subjected to western blot analysis. This assay showed the alterations at N74 of *PDCD1* decreased the expression of PD-1 protein. **Additional file 2: Figure S2.** CAR-T cells divided within tumor. Almost all the T cells (CD45^+^CD3^+^) accumulating within tumors were CAR-T cells (GFP^+^). In the infused T cells, about 85% were GFP^+^. In the activated T cells within tumors, the ratios of GFP^+^ cells were over 97%, indicating CAR-T cells but not the non-engineered cells divide upon antigen engagement *in vivo*. Untransduced T cells were used as control. **Additional file 3: Table S1.** Antibodies and materials list. **Additional file 4:.** Detailed method information and procedures of experiments.
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